Table of Contents Author Guidelines Submit a Manuscript
International Journal of Rheumatology
Volume 2011 (2011), Article ID 937843, 8 pages
Review Article

Targeting Nuclear Hormone Receptors: PPARα Agonists as Potential Disease-Modifying Drugs for Rheumatoid Arthritis

Laboratory of Clinical Immunopharmacology, Scientific Research Institute of Clinical Immunology, RAMS, 14 Yadrintsevskaya Street, Novosibirsk 630099, Russia

Received 30 December 2010; Revised 12 April 2011; Accepted 26 April 2011

Academic Editor: Malcolm Smith

Copyright © 2011 Ivan V. Shirinsky and Valery S. Shirinsky. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


In recent years, peroxisome proliferator-activated receptors (PPARs) have received growing interest due to the broad spectrum of their biological activities. PPARα, an isoform of PPAR, plays an important role in lipid homeostasis and inflammation, which makes it a potential target for the treatment of chronic inflammatory disorders, including RA. This paper reviews studies on the properties of PPARα agonists which may be pertinent to the treatment of RA. These properties include effects on lipid metabolism, inflammation, and angiogenesis, as well as interference with glucocorticoid effects, and a potential role in gender dimorphism of autoimmune disorders. However, current clinical experience with this class of drugs in RA is limited. New studies are needed to elucidate whether PPARα agonism may be an effective treatment strategy for RA patients.